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Abstract
Background: Low plasma betaine has been associated with unfavorable plasma lipid profiles and cardiovascular risk. In
some studies raised plasma betaine after supplementation is associated with elevations in plasma lipids. We aimed to
measure the relationships between plasma and urine betaine and plasma lipids, and the effects of lipid-lowering drugs on
these.
Methodology: Fasting plasma samples were collected from 531 subjects (and urine samples from 415) 4 months after
hospitalization for an acute coronary syndrome episode. In this cross-sectional study, plasma betaine and dimethylglycine
concentrations and urine excretions were compared with plasma lipid concentrations. Subgroup comparisons were made
for gender, with and without diabetes mellitus, and for drug treatment.
Principal Findings: Plasma betaine negatively correlated with triglyceride (Spearman’s rs=20.22, p,0.0001) and non-high-
density lipoprotein cholesterol (rs=20.27, p,0.0001). Plasma betaine was a predictor of BMI (p,0.05) and plasma non-
high-density lipoprotein cholesterol and triglyceride (p,0.001) independently of gender, age and the presence of diabetes.
Using data grouped by plasma betaine decile, increasing plasma betaine was linearly related to decreases in BMI (p=0.008)
and plasma non-HDL cholesterol (p=0.002). In a non-linear relationship betaine was negatively associated with elevated
plasma triglycerides (p=0.004) only for plasma betaine .45 mmol/L. Subjects taking statins had higher plasma betaine
concentrations (p,0.001). Subjects treated with a fibrate had lower plasma betaine (p=0.003) possibly caused by elevated
urine betaine loss (p,0.001). The ratio of coenzyme Q to non-high-density lipoprotein cholesterol was higher in subjects
with higher plasma betaine, and in subjects taking a statin.
Conclusion: Low plasma betaine concentrations correlated with an unfavourable lipid profile. Betaine deficiency may be
common in the study population. Controlled clinical trials of betaine supplementation should be conducted in appropriate
populations to determine whether correction affects cardiovascular risk.
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Introduction
Betaine (trimethylglycine, ‘‘TMG’’) is a dietary component [1,2],
and human betaine requirements can also be met by the metabolism
of choline [3,4]. Although it is a lipophobic metabolite, it has
physiological interactions with lipids. These have been studied in
farm animals and poultry because betaine is commonly included in
feeds to produce leaner meat with a lower fat content [5,6]. The
effects of betaine on blood and tissue lipids have been documented in
small animal models [7–9], suggesting that betaine supplementation
has a favourable effect on obesity-related health risk factors. In a rat
model, animals that gained more weight excreted more betaine than
other animals on the same diet [10], and conversely, obesity in mice,
induced by a high-fat diet, is associated with lowered liver betaine
[11], raising the possibility that the lipid load can cause changes in
tissue betaine.There is no consensus on how these observationsrelate
to the known functions of betaine, which are as an osmolyte in most
tissues, and as a store of methyl groups, mobilized in the liver by the
action of betaine homocysteine methyltransferase [3,4,6]. There is
conflicting evidence about the effect of betaine on lipids in human
subjects. In normal subjects, betaine supplementation for short
periods (6–12 weeks) may cause an increase in plasma betaine which
appears to be associated with a small elevation in plasma low-density
lipoprotein [12,13], though this was not apparent after 6 months of
supplementation [14]. In cross-sectional studies there is a negative
relationship between plasma betaine and plasma lipids, particularly
non-HDL cholesterol [15]. Cross-sectional results suggest that the
negative relationship between betaine and blood lipids is most
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21666prominent in metabolic syndrome patients [15] and in those with
lipid disorders [16], who may tend to be betaine deficient [3]. There
is a gender difference in the associations, with the effects stronger in
males than in females [15,17].
We have examined an acute coronary syndrome cohort for
relationships between betaine and its metabolite, N,N-dimethyl-
glycine, with plasma lipids and with lipid-lowering drugs. Betaine
is marketed as a nutritional supplement (often as ‘‘TMG’’) for
supposed cardiovascular benefits, although these claims are not
supported by controlled clinical trials; if its effect is to raise plasma
lipids there would be cause for concern. Conversely, cross-
sectional results suggest that there is a subset of the population,
possibly betaine-depleted [3], that may benefit from supplemen-
tation; if so, controlled trials with samples of those populations
should be undertaken, and the target groups for this therapy
defined [3,4].
Methods
Subjects
This was a cross-sectional sub-study in an Acute Coronary
Syndrome (ACS) cohort recruited by the Christchurch Cardioen-
docrine Group, Christchurch Hospital. Subjects had to have had
ischaemic discomfort plus one or more of the following: ECG
changes (ST segment depression or elevation of at least 0.5 mm,
T-wave inversion of at least 3 mm in at least 3 leads, or left bundle
branch block), elevated levels of cardiac markers, a history of
coronary disease, or age of at least 65 years in patients with
diabetes or vascular disease, i.e. identical criteria to those used in
the OPUS-TIMI 16 trial and in De Lemos et al. [18], to be eligible
for the study. Exclusion criteria: Severe co-morbidity limiting life
expectancy to less than 3 years. Inability to provide written
informed consent. For the betaine sub-study (Table 1) fasting
plasma samples were collected on 531 subjects, and matching
urine samples on 415 of these, at the four-month post-event follow-
up clinic visit.
Study protocols were approved by the Canterbury Ethics
Committee and all subjects gave written informed consent.
Laboratory methods
Betaine and N,N-dimethylglycine were measured in plasma and
urine by high performance liquid chromatography (HPLC) after
separation of their 2-naphthacyl derivatives on Merck Aluspher
alumina columns [19,20]. Plasma total coenzyme Q10 was
measured by HPLC with electrochemical detection [21]. Other
biochemical measures in plasma and urine were all carried out
using an Abbott ARCHITECT ci8200 Analyzer (Abbott Labo-
ratories); plasma cholesterol was measured by an enzymatic
cholesterol oxidase reaction, triglycerides by enzymatic hydrolysis
of triglycerides, both using Abbott reagents and HDL cholesterol
by an enzymatic reaction using Roche reagents (La Roche Ltd,
Switzerland). Urine creatinine was measured by the Jaffe ´ reaction.
Statistical analysis
Statistical analyses were carried out using SigmaPlot for
Windows version 11.2 (Systat Software Inc), which incorporates
SigmaStat.
None of the data were normally distributed, even after log-
transformation, therefore comparisons were based on ranking
methods. Spearman’s correlation coefficients were calculated. The
populations were divided into tertiles of the plasma betaine or lipid
fraction concentrations, and the differences of other metabolites in
the tertiles were compared using the Mann-Whitney Rank Sum
Test. Because of known gender differences in betaine metabolism
[15,17], male and female subgroups were analyzed separately.
Diabetes is frequently associated with increased betaine excretion
[3], therefore the effect of diabetes on the associations was
assessed.
Table 1. Study population.
Females Males
Number 148 383
Median age (total range), years** 73 (51291) 67 (55293)
Number with diabetes 28 65
Number taking fibrates 57
Number taking statins* 118 336
Number taking ACE inhibitors 76 212
Number taking b-blockers 123 328
BMI (median, IQ range) kg/m
2 27.0 (22.7231.6) 26.5 (24.5229.4)
Plasma triglyceride (median, IQ range) mmol/L 1.46 (1.0521.96) 1.49 (1.0322.06)
Plasma HDL-cholesterol (median, IQ range) mmol/L 1.25 (1.0621.54) 1.07 (0.9121.26)
Plasma non-HDL-cholesterol (median, IQ range) mmol/L 3.33 (2.5324.31) 2.99 (2.5023.67)
Plasma coenzyme Q (median, IQ range) mmol/L 0.65 (0.5220.87) 0.70 (0.5420.86)
Plasma betaine (median, IQ range) mmol/L*** 38.9 (30.8246.0) 44.5 (35.0257.5)
Plasma DMG (median, IQ range) mmol/L* 3.4 (2.224.8) 3.8 (2.725.2)
Urine betaine/creatinine (median, IQ range) mmol/mole cr 8.2 (4.4217.7) 9.2 (5.9217.6)
Urine DMG/creatinine (median, IQ range) mmol/mole cr 2.4 (1.424.3) 2.9 (1.525.9)
cr: creatinine. DMG: N,N-dimethylglycine. IQ: interquartile. HDL: high density lipoprotein. Significance of gender differences: *p,0.05;
**p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0021666.t001
Betaine and Lipids
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e21666Multiple linear regression models were calculated to identify
factors associated with plasma betaine and plasma lipid fractions.
Initially, multiple best subset regression models (6 to 30) were
calculated, including all plausible confounding factors, and the
most consistently significant variables in these were combined in
explicit multiple linear regression models. Where there was
significant variance inflation both of the affected variables were
added separately to explicit models. If some variables were no
longer significant in these models, a new model was calculated
omitting those variables, until models were obtained with all
variables significant and with variance inflation factors (VIF) ,2.
Because of the smaller numbers of urine samples, separate best
subset models were calculated including log-transformed urine
excretions of betaine and N,N-dimethylglycine.
The data was divided into deciles of plasma betaine
concentration to find underlying functional relationships between
plasma betaine and lipid fractions. The median plasma betaine
concentrations of the deciles were compared with the median
BMI and plasma lipid concentrations of the same groups, using
polynomial regression since not all relationships appeared to be
linear.
Results
General associations between lipids and betaine
In the total study population there were small but significant
correlations between betaine, its metabolite, N,N-dimethylglycine,
and plasma lipid fractions (Table 2). Higher plasma betaine
concentrations was associated with lower triglyceride and non-
HDL cholesterol concentrations (and also with lower calculated
LDL cholesterol). Coenzyme Q circulates mainly in low-density
lipoproteins, so it is not surprising that it also negatively correlated
with betaine; however, the ratio of coenzyme Q to non-HDL
cholesterol (or to calculated LDL-cholesterol) positively correlated
with betaine. The correlation between HDL cholesterol and the
ratio of dimethylglycine to betaine is rs=–0.15 (p=0.0005).
Best subset regression models (30) were calculated to identify
factors that appear to predict the plasma betaine concentrations.
None of these explained more than 25% of the variance in
plasma betaine (r
2,0.25), and notable factors that did not appear
as significant in any of them included age, diabetes, and plasma
glucose, electrolytes, triglyceride and creatinine. Using consis-
tently significant variables, explicit multiple regression models
(Figure 1) were calculated that showed that non-HDL
cholesterol was highly significantly negatively influenced by
plasma betaine concentrations and this was independent (VIF
1.04) of other significant factors; these included BMI (negative,
VIF 1.04) and gender (VIF 1.02). Plasma triglyceride only
appeared as a significant factor if non-HDL cholesterol was
excluded from the model. Conversely, factors significantly
affecting plasma betaine concentrations included and (negatively)
BMI and non-HDL cholesterol concentrations (Figure 1),
independently of other factors such as age, diabetes and statin
treatment. Plasma lipids were not included in these models
because of multicollinearity.
Plasma betaine concentrations appeared to be positively
associated with HDL-cholesterol in all 6 best subset models but
ceased to be significant when BMI was included in an explicit
multiple regression model rather than waist (only one of waist or
BMI was included to eliminate multicollinearity). The model for
HDL-cholesterol shown in Figure 1 can be slightly improved by
using the ratio of plasma dimethylglycine to betaine instead of
plasma dimethylglycine concentrations; this ratio term is more
significant (t=–3.13, p=0.002) than the concentration. Variables
that did not enter any of the best subset models as significant
factors include plasma homocysteine, creatinine and urea. Age
was not a significant factor in any of the models for plasma
betaine. The urinary excretions of betaine and dimethylglycine
were not significant in any of the models for predicting plasma
lipids or BMI that were calculated that included these urinary
measures.
In none of the models in Figure 1 was the explained variance
more than 20% of the total variance (r
2,0.2).
Blood pressure was not recorded in this study. Clinically-
diagnosed hypertension was recorded as a variable (0 or 1) but
given that the majority of subjects were receiving medication that
would modify blood pressure (Table 1) this was regarded as a
compromised measure; it did not enter into any of the best subset
models for blood lipid fractions, though it was a significant
predictor of BMI.
BMI and plasma non-HDL cholesterol concentrations de-
creased approximately linearly with increasing plasma betaine
concentrations (Figure 2), but the relationship with plasma
triglyceride concentrations was not linear, the binomial term
(Figure 2B) being significant (p=0.035). Above a plasma betaine
concentration of about 45 mmol/L no association was detected
between plasma betaine and triglyceride concentrations, whereas
low plasma betaine concentrations were strongly associated with
elevated plasma triglycerides. No significant relationship was
Table 2. Correlations in all subjects
1.
Plasma betaine Plasma DMG
2 Urine bet/creat
3 Urine DMG/cr
3
Triglyceride 20.220 (,0.0001) +0.026 (0.55) +0.04 (0.41) –0.026 (0.60)
HDL-cholesterol +0.023 (0.61) 20.130 (0.0031) –0.004 (0.94) –0.05 (0.28)
Non-HDL-chol
4 20.269 (,0.0001) –0.077 (0.079) –0.007 (0.89) –0.05 (0.34)
CoenzymeQ10 20.129 (0.0033) –0.04 (0.37) +0.098 (0.048) +0.111 (0.025)
CoQ/Non-HDL-c +0.134 (0.0024) +0.005 (0.92) +0.165 (0.001) +0.193 (0.0001)
BMI 20.158 (0.00047) –0.003 (0.94) –0.04 (0.39) –0.026 (0.62)
Age +0.054 (0.22) +0.109 (0.013) +0.038 (0.43) +0.028 (0.58)
1Spearman’s correlation coefficients (with p values). Significant (p,0.05) correlations indicated in bold.
2DMG: Dimethylglycine.
3Excretions expressed as ratio of urine betaine or DMG to creatinine.
4Non high density lipoprotein cholesterol.
doi:10.1371/journal.pone.0021666.t002
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(Figure 2C).
Comparisons in genders
The negative correlations between plasma betaine and
triglyceride or non-HDL cholesterol were highly significant in
the male subjects (Spearman’s rs=–0.25, p,0.0001 for triglycer-
ide, rs=–0.26, p,0.0001 for non-HDL cholesterol). They
appeared to be weaker in female subjects (rs=–0.16, p=0.051
for triglyceride, rs=–0.22, p=0.007 for non-HDL cholesterol)
though the differences between the correlation coefficients were
not significant. In males, top tertile median of plasma betaine
concentrations was 20 mmol/L (44%) higher than in the middle
tertile, whereas the lower tertile plasma betaine concentrations was
about 13 mmol/L (29%) lower. These differences tended to be
associated with lower plasma triglyceride, lower non-HDL
cholesterol or low BMI, and possibly with higher HDL-cholesterol
(Figure 3). In the smaller cohort of female patients the only
significant trend was with non-HDL cholesterol. The difference in
median plasma betaine concentration between top and bottom
tertiles was associated with approximately 25% lower plasma
triglyceride and 14% lower non-HDL cholesterol (Figure 3). The
relationship between plasma betaine and total coenzyme Q was
dominated by the strong relationships each had with non-HDL
cholesterol, giving a negative correlation, but the ratio of
coenzyme Q to non-HDL cholesterol (a measure of CoQ
Figure 1. Regression variables affecting plasma betaine concentrations, plasma lipid fractions and body mass index (BMI). Trig:
plasma triglyceride concentration; HDL-c: HDL cholesterol; non-HDL-c: non-HDL cholesterol (total cholesterol - HDL cholesterol). The bars are thet -
values of the significant variables, negative for variables with negative coefficients and positive for those with positive coefficients. Dashed vertical
lines indicate p=0.05; dotted vertical lines p=0.001. Numbers in brackets after variable names are the variance inflation factors. Pie figures on the
right show the portion of variance explained by regression (black). DMG: dimethylglycine.
doi:10.1371/journal.pone.0021666.g001
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betaine, at least in male patients.
The converse relationships were also significant. In males,
subjects in the bottom tertile of plasma triglyceride or bottom
tertile of plasma non-HDL cholesterol had significantly higher
plasma betaine concentrations (p,0.001) and those in the bottom
tertile of HDL-cholesterol or coenzyme Q10/non-HDL cholesterol
had lower plasma betaine (p=0.022 for HDL-cholesterol,
p=0.002 for the CoQ ratio). In females the apparent trends were
the same but were only statistically significant for non-HDL
cholesterol (p=0.001).
Plasma dimethylglycine did not correlate with either triglyceride
or with non-HDL cholesterol in either gender, but surprisingly
there was a negative correlation (rs=20.19, p=0.023) between
plasma dimethylglycine concentrations and HDL cholesterol in
females (in males, the correlation was not significant, rs=20.09,
p=0.095). When the ratio of dimethylglycine to betaine, an
indicator of active betaine metabolism, was compared with the
HDL cholesterol concentrations, there was a significant negative
correlation in both genders (rs=20.15, p=0.0048 in males;
rs=20.24, p=0.0047 in females).
Neither the urinary excretion of betaine nor of dimethylglycine
correlated with any of the plasma lipid fractions, in either gender.
The positive correlations of these urinary excretions with the
coenzyme Q to non-HDL cholesterol, or to calculated LDL-
cholesterol (Table 2) were not significant in the female subjects,
and were weak or not significant in the male subjects (p=0.092 for
betaine excretion, p=0.023 for dimethylglycine excretion) sug-
gesting that the results in Table 2 were strongly influenced by
gender differences in the variables being compared.
Effects of diabetes
As expected, diabetes is a significant factor in determining BMI
and plasma lipids (Figure 3) but not plasma betaine. Its
contribution to the multiple regression models is independent of
that of plasma betaine. In the groups of male and female patients
without diabetes, the same significant relationships were seen as
those in the whole male and female samples. The relationships
between plasma betaine and lipids were not detected as statistically
significant in the small groups of patients with diabetes (n=92).
The apparent trends were not significantly different from the
relationships seen in the total cohort, but there was insufficient
power to confirm that these trends were significant in the
subgroup. Only 4 subjects were diagnosed with type 1 diabetes.
Diabetic subjects frequently excrete excessive betaine [3], and in this
subgroup betaine excretion positively correlated with non-HDL
cholesterol (rs=+0.25, p=0.044, n=67). This association was not
seen.in subjects without diabetes (rs=20.06, p=0.32, n=329).
Effect of lipid-modifying drugs
The majority of the subjects were being treated with statins
(Table 1), and overall the median plasma betaine concentration
Figure 2. Plasma lipids and BMI as a function of plasma betaine concentrations. Data grouped into deciles based on the plasma betaine
concentrations, and median betaine concentrations of these plotted against A: median BMI, and the medians of the plasma lipid fractions (B:
triglycerides, C: HDL cholesterol, D: non-HDL cholesterol). Regression lines (with 95% confidence intervals) shown when significant, straight lines
(A&D) or curved (B) where the second order term is significant (p=0.035).
doi:10.1371/journal.pone.0021666.g002
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those not receiving statins (36.5 mmol/L, p,0.001). This was true
for both genders (Figure 4). There was no detectable difference in
the betaine excretions between subjects receiving statins and those
not (Figure 4). The median plasma dimethylglycine (3.7 mmol/L)
was the same in both groups, as was the dimethylglycine excretion
(2.7 mmol/mole creatinine). The subjects not receiving statins
tended to be slightly older. There were only modest differences in
the lipid profiles between the subjects receiving or not receiving
statins, as expected the plasma cholesterol in the subjects on statins
(median 4.2 mmol/L) was lower than in those not (5.2 mmol/L),
but the triglyceride and HDL-cholesterol concentrations were
almost identical. Total coenzyme Q concentrations were also
slightly lower (median 0.67 mmol/L cf 0.74 mmol/L, p=0.004) in
the subjects (both sexes) treated with statins, though the ratio of
coenzyme Q to non-HDL cholesterol was higher in the treated
patients (median 0.227 cf 0.195, p,0.001); a similar difference was
seen when the ratio of coenzyme Q to LDL cholesterol was
calculated.
There was plasma betaine data on only 12 subjects who were
being treated with a fibrate, all with bezafibrate. The median
plasma betaine concentration in these was lower than in subjects
not treated with fibrate (Figure 4). The urine betaine excretion
was estimated on 10 subjects treated with fibrate, and the median
excretion was significantly higher (p,0.001) than in those not
receiving fibrate (Figure 4). The urine dimethylglycine excretion
(median 8.8 mmol/mole creatinine) was also significantly
(p,0.001) higher than in subjects not taking fibrates (2.6 mmol/
mole creatinine). The plasma betaine concentration and betaine
excretion were negatively correlated in the fibrate-treated group
(Spearman’s rs=20.86; p=0.0018), significant despite there being
matching data on only 8 subjects. This suggested that betaine loss
may be an important factor in the lower plasma betaine found in
these subjects (Figure 5), and this association was not apparent in
other subgroups. The subjects treated with bezafibrate had a more
abnormal lipid profile than other subjects. The median plasma
triglyceride of 1.75 mmol/L was not significantly higher than the
1.48 mmol/L for non-fibrate treated subjects, but the median
non-HDL cholesterol of 3.83 mmol/L was significantly higher
than in subjects not taking a fibrate (3.07 mmol/L, p=0.002).
The estimates of the associations of betaine and plasma lipids
were not significantly changed by excluding the subjects taking
fibrates.
Only four subjects in this study were taking nicotinic acid. The
median plasma betaine concentration in the treated subjects was
47.0 mmol/L, not significantly different from the median in the
other 515 subjects (42.0 mmol/L). In contrast to the fibrate group,
the median urine betaine excretion in the nicotinic acid treated
group (n=3) was 3.3 mmol/mole creatinine compared with
9.1 mmol/mole creatinine in the other subjects (n=414;
Figure 3. Plasma lipids and BMI in male (n=382) and female
(n=150) patients with different tertiles of plasma betaine
concentrations. The solid boxes show the interquartile ranges, with
the medians indicated, and the cap the 90%-ile, of the (A–C) plasma
lipid concentrations in the subject groups, D the BMIs of the subjects,
and E. for comparison, the plasma betaine concentrations in the tertiles.
The significance (left) indicates whether there was a difference between
the tertiles (ANOVA on ranks).
doi:10.1371/journal.pone.0021666.g003
Figure 4. Plasma betaine concentrations in subjects being
treated with lipid-lowering drugs; A: plasma betaine concen-
trations and B. urinary betaine excretions. The solid boxes show
the interquartile ranges, with the medians indicated, and the cap the
90%-ile, of the A. plasma betaine concentrations and B. urinary betaine
excretions in the subject groups. The significance of the differences
(Mann-Whitney Rank Sum Test) are shown.
doi:10.1371/journal.pone.0021666.g004
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there was no suggestion of an increase in excretion comparable to
that seen with fibrate treatment; if anything it was more likely to be
in the reverse direction.
Discussion
Interaction of plasma betaine and lipids
Plasma betaine and lipids clearly interact, with 15–20% of the
variance in each being associated with variance the other.
Although the causal direction has not been assumed here, it is
more likely that betaine is affecting the lipids. A reason to add this
assumption is the evidence that an increased betaine intake
increases plasma betaine and favorably affects lipid distribution in
the body; the animal industries include betaine in animal feeds to
produce better meat, more lean muscle mass and less fat [5,6], in
other words, to decrease obesity. These effects are best
documented in pigs, both in growing piglets and in adult animals,
but similar effects are well known in poultry [22,23]. In small
animal models, when hyperhomocysteinemic mice were supple-
mented for a year, plasma triglycerides decreased while HDL-
cholesterol increased; other improvements in the atherogenic risk
factor profile were also observed [8]. Betaine therapy also
attenuates atherosclerosis in the apoE knockout mouse [9].
However, human intervention studies have suggested an opposite
effect on plasma lipids: healthy but overweight subjects supplied a
betaine supplement to increase their plasma betaine concentra-
tions had a significant increase in plasma cholesterol [12], and
Olthof et al. [13] questioned the safety of betaine supplementation
on the basis of a small elevation in plasma triglycerides and LDL
cholesterol in subjects receiving betaine supplements. Betaine
supplementation can increase plasma lipids in small animal
models; in an apolipoprotein E-deficient mouse model, which
develops atherosclerotic lesions [9], betaine supplementation
increased plasma cholesterol (though not triglycerides) at the same
time as it decreased atherosclerotic lesion areas. The physiological
significance of the possible rise in plasma lipids during betaine
supplementation has been questioned [24], and a group of non-
obese healthy younger adults treated with betaine for six months
showed insignificant changes in plasma lipids [14]. Another study
detected a small decrease in plasma lipids after a modest betaine
supplementation [25].
Resolving the contrary indications from cross sectional
studies
A large cross-sectional study of a Norwegian population [15]
showed a highly significant negative association between plasma
betaine concentrations and both plasma lipids and markers of
obesity (BMI, percent body fat and waist circumference). Consistent
with the results reported here, higher plasma betaine was associated
with plasma triglyceride and non-HDL cholesterol, with the effect
more pronounced in men than in women; there was a trend for
HDL cholesterol to be weakly positively associated with plasma
betaine but this was only statistically significant in younger (47–49
years) males. These results are consistent with the suggestion that
betaine can be deficient in patients with symptoms of the metabolic
syndrome [3], and because of the tight regulation of plasma betaine
[26,27]thismaynotalways bedetected asplasma concentrationsdo
not reliably reflect tissue levels. Here, we have shown that the
association of betaine with BMI and lipid components of the
metabolic syndrome are clearly independent of each other and of
potential confounders such as gender, age and diabetes (variance
inflation factors ,1.05 in multiple regression models).
Other animal studies suggest that betaine affects the partitioning
of lipid in the body, and in particular increases the export of tissue
triglycerides. In normal rats, betaine supplementation (especially
when the methionine supply is restricted) leads to increased
hepatic production of apolipoprotein B [28] and increased plasma
LDL and triglycerides, and these changes are associated with a
large decrease in tissue lipid, which has been confirmed in other
studies [7]. The overall effect of increased betaine intake probably
depends on other dietary components (as shown in rats [7]), the
presence of disease, and tissue lipids. Two contrasting studies in
pigs illustrate this point: betaine supplementation increased plasma
lipids in castrated pigs of a genetically obese strain [29], whereas a
lower level of betaine supplementation decreased plasma lipids in
non-obese female pigs [30]. A possible dose dependence of the
effect of plasma betaine on lipids was suggested by Konstantinova
et al. [15], and it is also plausible that the effect of betaine on
plasma lipids depends on tissue lipid stores. This is consistent with
cross-sectional human data which suggests that those subjects with
the combination of elevated triglyceride and non-HDL cholesterol
with low plasma betaine are likely to show features of the
metabolic syndrome [15,16].
In a contrasting recent cross-sectional study, plasma concen-
trations of trimethylamine N-oxide, choline and betaine are all
reported to be associated with an increased number of vascular
events in an at-risk population [31]. It is proposed that the causal
agent is trimethylamine or its N-oxide; trimethylamine is
produced in the gut by bacterial metabolism of choline and
oxidized in the liver to its N-oxide. This cannot account for the
betaine results because betaine is not converted to trimethylamine
in the gut [32]. Betaine concentrations in tissues, where it
functions as an osmolyte, are orders of magnitude higher than in
plasma [33] therefore elevated betaine concentrations themselves
are unlikely to cause damage. Our preliminary prospective results
(unpublished data) could reconcile these inconsistencies: although
low plasma betaine concentrations were a more significant risk
factor for myocardial infarction, there was also an increased risk
Figure 5. Plasma betaine concentration as a function of urine
betaine excretions in subjects treated with fibrate. Spearman’s
r=20.86; p=0.0018.
doi:10.1371/journal.pone.0021666.g005
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there were some patients whose control of betaine efflux from
tissues is compromised, and this subgroup is prone to early
events.
Cross-sectional studies and mechanisms
Cross-sectional studies do not demonstrate causality, but
generate hypotheses. This is also illustrated by the effects of lipid
lowering drugs on plasma betaine concentrations and urinary
betaine excretion. Are the differences caused by the drug
treatment, or do they reflect differences in the patients that are
prescribed those drugs? In the case of statins, there is no reason
to suspect that the patients treated with statins differed
significantly from the minority who were not receiving statins,
and it is likely that an increase in plasma betaine is another
pleotropic effect of statins[34]. Fibrates, however, almost
certainly cause increased betaine excretion [35] and since this
is negatively correlated with the plasma betaine it is plausible to
s u g g e s tt h a ti ti sac a u s eo ft h el o w e rp l a s m ab e t a i n ei nt h e s e
patients. Fibrate treatment is therefore inducing a betaine
deficiency, which may compromise the benefits of fibrate.
Subjects being prescribed fibrate would be expected to have
elevated triglyceride and low-density lipoprotein, so finding a
difference in these (and the LDL- associated coenzyme Q) in
fibrate-treated patients is a trivial result that has no necessary
connection with the differences in plasma betaine. There were
too few subjects taking nicotinic acid to detect any significant
effects on plasma and urine betaine, but the limited data
suggests that this drug does not cause a comparable effect to that
seen with bezafibrate. The negative effect of statin therapy on
plasma coenzyme Q is well-known, but when expressed as a
r a t i ot on o n - H D Lc h o l e s t e r o l( or LDL-cholesterol) the appar-
ently available coenzyme Q is higher in patients receiving
statins. There is a similar association between plasma betaine
a n dc o e n z y m eQ ,s u g g e s t i n gt h a th i g h e rp l a s m ab e t a i n e
concentrations are associated with a more favorable coenzyme
Q status.
Konstantinova et al [15] concluded that metabolic syndrome
patients had lowered plasma betaine concentrations but elevated
plasma choline concentrations. This is consistent with a conjecture
that betaine deficiency is not generally associated with choline
deficiency, but instead betaine deficiency may often reflect
impaired mitochondrial conversion of choline to betaine, a major
source of betaine. Choline is itself essential and central to
phospholipid (and hence lipoprotein) synthesis, and betaine is
not a source of choline. The effects of each on lipid metabolism
seem to be independent of the other, but again this is surmised
from cross-sectional data and needs to be verified experimentally.
Vascular disease can cause an increase in plasma free choline [36]
(as a result of phospholipid breakdown), which complicates
interpretation of the relationship between plasma choline and
betaine: plasma betaine is normally controlled by the enzyme
betaine homocysteine methyltransferase in the liver [3,37]. This
explains why, in several studies [15,31], the positive correlations
between plasma choline and betaine are modest (typically r,0.3).
Our study supports the earlier report [15] that the metabolic
syndrome is often associated with a combination of low plasma
betaine and an atherogenic lipid profile by showing that BMI and
plasma lipids are independently related to plasma betaine.
Although this cross-sectional data does not demonstrate causality,
the relationship between plasma triglycerides and betaine is
consistent with the suggestion of Konstantinova et al. [15] that the
effects of betaine are dose dependent, so that increasing the
betaine intake of a betaine replete subject may not necessarily be
beneficial.
Our, and other, cross-sectional results suggest a testable
hypothesis that a betaine deficiency is associated with an
atherogenic lipid profile. Further hypotheses are that betaine
supplementation of betaine-deficient subjects will improve their
lipid profiles, and will decrease their vascular risk, though there
might be a short term increase in plasma lipids in obese subjects.
These hypotheses suggest that long-term controlled trials of
betaine supplementation are needed, especially ones that target
populations that are likely to be betaine deficient. Previous
human supplementation studies have excluded subjects likely to
be betaine deficient [12,14]. In the present study, the difference
in plasma betaine between top and bottom tertiles is about
30 mmol/L, and this is associated with an approximately 25%
difference in plasma triglyceride and a 14% difference in non-
HDL cholesterol. These data imply substantial differences in
cardiovascular risk. It should be tested whether changing the
betaine concentrations alters risk: increasing plasma betaine by
regular supplementation is easily achieved and inexpensive.
Hypotheses about mechanisms need to consider both the
osmolyte role of betaine, and (especially in view of the
relationship between dimethylglycine and HDL-cholesterol) the
m e t h y ls t o r er o l eo fb e t a i n e ,a n dm a yb e s tb ea d d r e s s e di n
animal models where tissue betaine contents can also be
measured.
Limitations
As discussed, the cross-sectional design only generates hypoth-
eses and does not demonstrate causality. The limited numbers in
subgroups (especially female subjects and subjects with diabetes)
means that there are some negative results that should be regarded
with caution. The population is a selected one (with established
vascular disease and highly medicated) and therefore the results of
this study do not necessarily reflect those that would be found in
the general population.
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